美国前列腺癌生物标记市场规模、份额和趋势分析报告：按类型、应用、最终用途和细分市场预测，2025-2033 年

市场规模和趋势

预计 2024 年美国前列腺癌生物标记市场价值将达到 17 亿美元，预计 2025 年至 2033 年期间的复合年增长率为 14.74%。

前列腺癌盛行率的上升、早期检测意识的增强以及精准诊断技术的普及推动了市场的成长。液态切片、基因组学和非侵入性生物标记技术的进步正在提高筛检的准确性和患者分层。此外，个人化治疗方案的需求不断增长，以及PSA、PCA3和基因表现检测（例如Decipher和Oncotype DX）的优惠报销框架，也进一步推动了市场的成长。策略伙伴关係和持续的研发投入也正在扩大生物标誌物的产品线和商业性应用。

前列腺癌是美国男性最常见的恶性肿瘤之一。根据美国癌症协会的数据，八分之一的男性在其一生中会被诊断出患有这种疾病。仅在 2022 年，就将报告约 268,500 例新患者，导致约 34,500 人死亡，使其成为美国男性癌症死亡的第二大原因。目前，美国有超过 310 万名男性罹患摄护腺癌。如此高的盛行率，加上 PSA 检测等传统诊断方法的局限性，缺乏区分良性和恶性疾病的特异性，因此对能够早期发现、风险分层和个性化治疗的新型生物标誌物的需求强烈。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国前列腺癌生物标记市场变数、趋势和范围

• 美国前列腺癌生物标记市场的系统展望
  • 母市场展望
• 渗透和成长前景图
• 管道分析
  • 筛检和早期检测
  • 诊断和风险分层
  • 预后和治疗监测
  • 伴随诊断
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 前列腺癌生物标记：市场分析工具
  • 产业分析—波特五力分析
  • PESTLE分析

第四章美国前列腺癌生物标记市场：細項分析（按类型），2021-2033 年

• 美国前列腺癌生物标记市场：类型变异分析

第五章美国前列腺癌生物标记市场：細項分析、应用、2021-2033

• 美国前列腺癌生物标记市场：应用差异分析

第六章美国前列腺癌生物标记市场：細項分析（按最终用途），2021-2033 年

• 美国前列腺癌生物标记市场：最终用途变异分析

第七章美国前列腺癌生物标记市场：竞争分析

• 公司分类
• 战略地图
  • 新产品发布
  • 伙伴关係
  • 获得
  • 合作
  • 资金筹措
• 2022年企业市场占有率分析
• 公司简介
  • Exact Sciences Corporation
  • Myriad Genetics, Inc.
  • Bio-techne
  • Exodx
  • Opko Health, Inc.
  • Mdxhealth
  • Veracyte, Inc.
  • Beckman Coulter, Inc.
  • Nucleix
  • Diacarta

Market Size & Trends:

The U.S. prostate cancer biomarkers market size was estimated at USD 1.7 billion in 2024 and is expected to grow at a CAGR of 14.74% from 2025 to 2033. The market growth is driven by the rising prevalence of prostate cancer, awareness around early detection, and adoption of precision diagnostics. Advancements in liquid biopsy, genomics, and non-invasive biomarker technologies are enhancing screening accuracy and patient stratification. Additionally, the rising demand for personalized treatment planning, along with favorable reimbursement frameworks for diagnostic tests such as PSA, PCA3, and gene-expression panels (e.g., Decipher, Oncotype DX), is further accelerating market growth. Strategic collaborations and continuous R&D investment are also expanding the biomarker pipeline and commercial availability.

Prostate cancer is one of the most prevalent malignancies affecting men in the United States. According to the American Cancer Society, 1 in 8 men will be diagnosed with the disease in their lifetime. In 2022 alone, an estimated 268,500 new cases were reported, with approximately 34,500 deaths, making it the second leading cause of cancer death among American men. Today, over 3.1 million men in the U.S. are living with prostate cancer. This substantial patient population, along with limitations in traditional diagnostics such as PSA testing, which lacks specificity to distinguish between benign and malignant conditions, has created strong demand for novel biomarkers that can enable earlier detection, improved risk stratification, and treatment personalization.

U.S. Prostate Cancer Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-markets from 2021 to 2033. For this study, Grand View Research has segmented the U.S. prostate cancer biomarkers market report based on type, application, and end-use:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Genetic Biomarkers
  • Protein Biomarkers
  • Cell-based Biomarkers
  • Metabolomic Biomarkers
• Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Screening and Early Detection
  • Diagnosis and Risk Stratification
  • Prognosis and Treatment Monitoring
  • Companion Diagnostics
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Diagnostic Laboratories
  • Academic and Research Institutes
  • Biopharmaceutical Companies

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation And Scope
  • 1.1.1 Segment Definition
    • 1.1.1.1 Application Segment
    • 1.1.1.2 Type Segment
    • 1.1.1.3 End USE Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 GVR's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Outlook
• 2.2 Application And Type Snapshot
• 2.3 End USE Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 U.S. Prostate Cancer Biomarkers Market Variables, Trends, And Scope

• 3.1 U.S. Prostate Cancer Biomarkers Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Pipeline Analysis
  • 3.3.1 Screening And Early Detection
  • 3.3.2 Diagnosis And Risk Stratification
  • 3.3.3 Prognosis And Treatment Monitoring
  • 3.3.4 Companion Diagnostics
• 3.4 Market Dynamics
  • 3.4.1 Market Driver Analysis
    • 3.4.1.1 Rising Prevalence Of Prostate Cancer
    • 3.4.1.2 Advancements In Genomic And Proteomic Technologies
    • 3.4.1.3 Supportive Government And Research Initiatives
  • 3.4.2 Market Restraint Analysis
    • 3.4.2.1 High Cost Of Biomarker-based Tests
    • 3.4.2.2 Uneven Access To Advanced Diagnostic Infrastructure
• 3.5 Prostate Cancer Biomarkers: Market Analysis Tools
  • 3.5.1 Industry Analysis - Porter's
  • 3.5.2 Pestle Analysis

Chapter 4 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By Type, 2021 - 2033 (USD Million)

• 4.1 U.S. Prostate Cancer Biomarkers Market: Type Movement Analysis
  • 4.1.1 Genetic Biomarkers
    • 4.1.1.1 Genetic Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)
  • 4.1.2 Protein Biomarkers
    • 4.1.2.1 Protein Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)
  • 4.1.3 Cell-based Biomarkers
    • 4.1.3.1 Cell-based Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)
  • 4.1.5 Metabolomic Biomarkers
    • 4.1.5.1 Metabolomic Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)

Chapter 5 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By Application, 2021 - 2033 (USD Million)

• 5.1 U.S. Prostate Cancer Biomarkers Market: Application Movement Analysis
  • 5.1.1 Screening And Early Detection
    • 5.1.1.1 Screening And Early Detection Market, 2021 - 2033 (USD Million)
  • 5.1.2 Diagnosis And Risk Stratification
  • 515.2.1 Diagnosis And Risk Stratification Market, 2021 - 2033 (USD Million)
  • 5.1.3 Prognosis And Treatment Monitoring
  • 51.3.1 Prognosis And Treatment Monitoring Market, 2021 - 2033 (USD Million)
  • 5.1.4 Companion Diagnostics
    • 5.1.4.1 Companion Diagnostics Market, 2021 - 2033 (USD Million)

Chapter 6 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By End USE, 2021 - 2033 (USD Million)

• 6.1 U.S. Prostate Cancer Biomarkers Market: End USE Movement Analysis
  • 6.1.1 Hospitals And Diagnostic Laboratories
    • 6.1.1.1 Hospitals And Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
  • 6.1.2 Academic And Research Institutes
    • 6.1.2.1 Academic And Research Institutes Market, 2021 - 2033 (USD Million)
  • 6.1.3 Biopharmaceutical Companies
    • 6.1.3.1 Biopharmaceutical Companies Market, 2021 - 2033 (USD Million)

Chapter 7 U.S. Prostate Cancer Biomarkers Market: Competitive Analysis

• 7.1 Company Categorization
• 7.2 Strategy Mapping
  • 7.2.1 New Product Launch
  • 7.2.2 Partnerships
  • 7.2.3 Acquisition
  • 7.2.4 Collaboration
  • 7.2.5 Funding
• 7.3 Company Market Share Analysis, 2022
• 7.4 Company Profiles
  • 7.4.1 Exact Sciences Corporation
    • 7.4.1.1 Company Overview
    • 7.4.1.2 Financial Performance
    • 7.4.1.3 Product Benchmarking
    • 7.4.1.4 Strategic Initiatives
  • 7.4.2 Myriad Genetics, Inc.
    • 7.4.2.1 Company Overview
    • 7.4.2.2 Financial Performance
    • 7.4.2.3 Product Benchmarking
    • 7.4.2.4 Strategic Initiatives
  • 7.4.3 Bio-techne
    • 7.4.3.1 Company Overview
    • 7.4.3.2 Financial Performance
    • 7.4.3.3 Product Benchmarking
    • 7.4.3.4 Strategic Initiatives
  • 7.4.4 Exodx
    • 7.4.4.1 Company Overview
    • 7.4.4.2 Product Benchmarking
  • 7.4.5 Opko Health, Inc.
    • 7.4.5.1 Company Overview
    • 7.4.5.2 Product Benchmarking
    • 7.4.5.3 Strategic Initiatives
  • 7.4.6 Mdxhealth
    • 7.4.6.1 Company Overview
    • 7.4.6.2 Financial Performance
    • 7.4.6.3 Product Benchmarking
    • 7.4.6.4 Strategic Initiatives
  • 7.4.7 Veracyte, Inc.
    • 7.4.7.1 Company Overview
    • 7.4.7.2 Financial Performance
    • 7.4.7.3 Product Benchmarking
    • 7.4.7.4 Strategic Initiatives
  • 7.4.8 Beckman Coulter, Inc.
    • 7.4.8.1 Company Overview
    • 7.4.8.2 Product Benchmarking
  • 7.4.9 Nucleix
    • 7.4.9.1 Company Overview
    • 7.4.9.2 Financial Performance
    • 7.4.9.3 Product Benchmarking
    • 7.4.9.4 Strategic Initiatives
  • 7.4.10 Diacarta
    • 7.4.10.1 Company Overview
    • 7.4.10.2 Product Benchmarking
    • 7.4.10.3 Strategic Initiatives

List of Tables

• Table 1 List of Abbreviations
• Table 2 U.S. prostate cancer biomarkers market, by application, 2021 - 2033 (USD Million)
• Table 3 U.S. prostate cancer biomarkers market, by type, 2021 - 2033 (USD Million)
• Table 4 U.S. prostate cancer biomarkers market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Prostate Cancer Biomarkers market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot (Type and application)
• Fig. 11 Segment snapshot (End use)
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Biomarkers market value, 2024 (USD Million)
• Fig. 14 Prostate Cancer Biomarkers market dynamics
• Fig. 15 Prevalence of Screening and Early Detection by age group, 2024
• Fig. 16 Prostate Cancer Biomarkers market: PORTER's analysis
• Fig. 17 Prostate Cancer Biomarkers market: PESTLE analysis
• Fig. 18 Prostate Cancer Biomarkers market: Type outlook and key takeaways
• Fig. 19 Prostate Cancer Biomarkers market: Type movement analysis
• Fig. 20 Genetic Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 21 Protein Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 22 Cell-based Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 23 Metabolomic Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 24 Prostate Cancer Biomarkers market: Application outlook and key takeaways
• Fig. 25 Prostate Cancer Biomarkers market: Application movement analysis
• Fig. 26 Screening and Early Detection market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 27 Diagnosis and Risk Stratification market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 28 Prognosis and Treatment Monitoring market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 29 Companion Diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 30 Prostate Cancer Biomarkers market: End use outlook and key takeaways
• Fig. 31 Prostate Cancer Biomarkers market: End use movement analysis
• Fig. 32 Hospitals and Diagnostic Laboratories market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 33 Academic and Research Institutes market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 34 Biopharmaceutical Companies market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 35 Key company categorization
• Fig. 36 Company market positioning
• Fig. 37 Company market share analysis, 2024
• Fig. 38 Strategic framework